DexCom announced a series of governance enhancements ahead of its 2026 Investor Day presentation, including plans to add two new independent directors with MedTech and operations expertise, reconstitute a key board committee, and deepen operational oversight as the company positions itself for long-term growth.
The company said the initiatives follow constructive engagement with Elliott Investment Management L.P.. Dexcom and Elliott have agreed to collaborate on identifying two new independent board members with backgrounds in MedTech leadership or lean operations. The appointments are intended to strengthen oversight and support the company’s operational scaling and global expansion efforts. Following the additions, Dexcom will have appointed six new independent directors since the beginning of 2023.
Dexcom also announced that its existing Technology Committee will be renamed the Operations and Innovation Committee. The expanded committee mandate will include oversight of operations, quality initiatives, and the company’s technical roadmap, reflecting a broader emphasis on operational execution and customer experience.
The governance updates were announced in conjunction with Dexcom’s Investor Day event, where the company plans to outline its strategic and financial vision focused on advancing metabolic health through its biosensing platforms.
Jake Leach, President and CEO of Dexcom, said the board enhancements align with the company’s focus on uncompromising quality, customer experience, and long-term execution. Lead Independent Director Mark Foletta added that the board remains committed to continual refreshment and strengthening its expertise to support Dexcom’s next phase of growth.
Marc Steinberg, Partner at Elliott, said the firm believes the continuous glucose monitoring market remains significantly underpenetrated and that Dexcom is positioned to deliver sustained double-digit growth alongside meaningful margin expansion. He added that the company’s governance and operational initiatives create a strong framework for long-term value creation.
Founded in 1999, DexCom, Inc. develops glucose biosensing technology used in diabetes management and metabolic health monitoring.
KEY QUOTES:
“We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosensing platforms. Today’s announcement of enhancements to our Board structure aligns closely to our vision for uncompromising quality and customer experience, as well as updates we’ve made to our organizational structure to support the execution of our long-term plan.”
Jake Leach, President and CEO, Dexcom
“Our Board is always focused on continual refreshment that adds the skills and experience that will take our company to the next level. We are excited to announce this plan to further bolster our Board’s composition.”
Mark Foletta, Lead Independent Director, Dexcom
“We are one of Dexcom’s largest investors because of our conviction that the CGM market remains meaningfully underpenetrated and that the company is poised to deliver sustained double-digit growth for years to come. We also see a clear path to significant margin expansion, underpinning one of the most compelling earnings growth profiles in MedTech. Dexcom is taking the right steps to realize its potential, including the upcoming addition of new directors with deep medical technology and operating experience, the oversight of a dedicated committee of the Board, and a strengthened commitment to disciplined operational rigor and capital allocation. We are pleased to be working alongside Jake Leach and the Board to ensure Dexcom can realize the full extent of the value creation opportunity before it.”
Marc Steinberg, Partner, Elliott Investment Management L.P.
